The Role of Tumor Necrosis Factor-alpha as a Marker of Inflammation and a Predictor of in-hospital Complications in Patients with Acute Coronary Syndrome

1Sally Abdul-Raheem Alhumrani * B.Sc Biology
2Nidham M. Jamalludeen* M.Sc, PhD
3Abdulameer Abdulbari Abdulhameed** FIBMS, CABM (Interventional Cardiologist)

*Department of Microbiology
College of Medicine
University of Basrah
Basrah, Iraq

** Department of Medicine
College of Medicine
University of Basrah
Basrah, Iraq


Abstract

Background

Acute coronary syndromes are caused by rupture of plaques or erosion that leads to local clotting formation of coronary blood flow eventually blocking to necrosis or ischemia of myocardial cells. Prognosis; other markers of inflammation may play similar role. Cytokines are responsible for modulating immune and inflammatory processes as well as both proliferative and apoptotic responses. Tumor necrosis factor (TNF-α): It is an important cytokine involved in systemic inflammation. This study aimed to measure TNF-α level and its association with hospital complications in patients with the acute coronary syndrome.

Method:

One hundred and twenty-five patients with acute coronary syndrome and 120 healthy individuals as a control group

According to ECG and serum troponin changes, the patient group was classified into three; ST-elevated myocardial infarction, ST non-elevated myocardial infarction and unstable angina.

Sandwich ELISA was used by commercial groups (LEGAND MAXTM) for the TNF-α assay.

Result:

This study shows highly significant differences in the level of TNF-α in patient with acute coronary syndrome (27.49) as compared with the control group (10.62) (P. value 0.001)

There were no statistically significant differences in the level of TNF-α in patients with acute coronary syndrome and some traditional risk factors like gender (P. value 0.25).

There were statistically significant differences in the level of TNF-α in all forms of ACS and control group p-value 0.001
Patients with in hospital complication had higher level of TNF-α (33.46 Pg/dl) than those without complication (24.15 Pg/dl) P-value (0.041).

**Conclusion:**
This study indicated that TNF-α was significantly elevated in patients with ACS and maybe a good predictor not only of acute coronary event but also disease severity and prognosis for complications.

**Keywords** ACS, TNF-α, STEMI, NSTEMI, unstable angina, complications

**Introduction:**
Inflammation plays a pivotal role not only in the chronic form of atherosclerosis (clinically manifested as stable angina) but also in acute coronary event (the acute coronary syndrome)

Acute coronary syndromes result from plaque rupture or erosion leading to local thrombus formation obstruction of coronary blood flow ultimately to necrosis or ischemia of cardiac myocyte. Cardiac troponin and C reactive protein is a good marker for diagnosis and prognosis; other markers of inflammation may play a great role as well.[1]

Cytokines are responsible for the modulation of immunological and inflammatory processes as well as proliferative responses and apoptosis.[2]

Tumor necrosis factor (TNF-α): is one of the important cytokines involved in systemic inflammation and makes up the acute phase reaction. TNF-α is a potent pro-inflammatory cytokine exerting pleiotropic effects on various cell types and plays a critical role in the pathogenesis of chronic inflammatory diseases, such as Rheumatoid arthritis. [3, 4]

It is produced chiefly by activated macrophages, although it can be produced by many other cell types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons. It also synthesized in various blood, endothelial and smooth muscle cells, and in cardiac myocytes. [5]

The presence of TNF-α in the majority of atherosclerotic lesions and absence from normal tissues suggests its involvement in the pathogenesis of atherosclerosis. TNF-α may contribute to the inflammatory process of atherosclerosis by activation of growth factors, other cytokines, and by affecting the synthesis and stimulation of adhesion molecules. [6]

The ubiquity and function of its 2 receptors provide it with the capacity to modulate acute coronary diversity of inflammatory processes which are strongly involved in acute coronary syndrome (ACS) [7] and in the development of heart failure due to its negative inotropic action. [8]. Therefore this study aimed to measure the level of TNF-α in patients with ACS and study their role as an early marker of inflammation in the indifferent form of ACS, whether it correlates with in-hospital complications
Method
One hundred twenty-five patients with acute coronary syndrome and 120 persons as a control group were included in this study for the period from March 2019 to January 2020. Their age range from 31 to 95 with mean (58.72 ± 12.32 SD). Ethical approval was getting from the committee board of the Iraqi health and higher education authority before start collection the samples.

Fifty-seven (45.6 %) were females and 68 (54.4 %) were males. A review of history was taken, physical examinations were done. Routine blood count and serum biochemistry were requested.

Twelve leads Electrocardiography was done and review by expert cardiologists. According to electrocardiography changes and serum troponin, the patients group was sub-classified into three subgroups ST-elevation myocardial infarction (STEMI), Non-ST-elevation myocardial infarction (NSTEMI), and unstable angina(UA) groups.

Five ml of venous blood samples where obtained from all patients at time of admission to CCU at Albasrah teaching hospital and Alsader teaching hospital and prepared for TNF-α level assay.

Sandwich ELISA was used by commercial kits (LEGAND MAX TM) for TNF-α assay. The procedure was performed according to kit manufacture instruction company and ELISA done in the Albian lab.

Statistical Analysis
The data were analyzed SPSS version 17. Means and standard deviation were used to describe the data distribution. ANOVA or F-test was used for the comparison of more than two means, when analysis significant, Post hoc test used to determine within the group analysis significantly. Independent t-test used to determine significance between the means of two groups. The test was considered significant if the P. value was less than 0.05.

Result:
Out of 125 patients with ACS; STEMI was the commonest form reported 75 (60%) patients, followed by UA 29 (23.3%) patients, and NSTEMI 21 (16.8%) patients.
This study demonstrated a high level of TNF-α in patients with ACS (27.49 Pg/dl) than the control group (10.62 Pg/dl). This difference was statistically highly significant (P. value 0.001).
All form of ACS (STEMI, NSTEMI and UA) have higher TNF-α levels in comparism with the control group. (Table 1)
There were no astatically significant differences in the level of TNF-α when different form of ACS compare with each other (STEMI Vs NSTEMI, STEMI Vs UA, and NSTEMI Vs UA) P.value; (0.95, 0.19, and 0.70 respectively)
This study demonstrated that there were no statistically significant differences between the traditional risk factors that were studied (age, smoking, hypertension, diabetes mellitus, obesity) and the level of TNF-α in patient with ACS. (Table2).
There were statistically significant differences in the mean level of TNF-α in patients with complication (33.46 pg/dl) and without complication (24.15 pg/dl) in ACS (P. value 0.041) (Table 3).

Despite heart failure was the commonest complication in the patients that were studied, there were no significant differences between the mean level of TNF-α in patients with heart failure versus those patients with other complications (P. value =0.897). (Table 4)

Another interesting finding this study reported there were no statistically significant differences on the effect of gender on TNF-α level among different form of ACS (P. value 0.210) (Table 5)

**Discussion:**

The roles of pro-inflammatory and anti-inflammatory cytokine in the pathogenesis of the disease get great consideration in recent studies. A balance between proinflammatory and anti-inflammatory cytokines is necessary to maintain health. [9]

Although several cytokines (IL-1β, IL-6, IL-23, IL-27, IL-33), associated with an increased risk of atherosclerosis. [10]

Low level of interleukin-10 (as anti-inflammatory cytokine), have been associated with an increased risk of cardiovascular events and high IL-10 level have been associated with a decreased risk of ACS [11,12]

The role of the pro-inflammatory cytokine TNF-α in ACS was the focus of our concern in this study.

TNF-α level was significantly elevated in patients with ACS (27.49 pg/dl) than control group (10.62 pg/dl) (p. value 0.001) (Table 1). This was in agreement with other studies [13-16]

Ridker et al., have reported that plasma concentration of TNF-α remains elevated many months after myocardial infarction and that very high levels are associated with an increased risk of recurrent coronary events [17]

Recently, it is believed that TNF-α is one of the main proinflammatory cytokines and plays a central role in initiating and regulating the cytokine cascade during an inflammatory response and plays an important role in the pathogenesis of atherosclerosis and acute coronary syndromes. [6]

Simon et al. were administered that increase the level of pro-inflammatory cytokine concentrations were important and also decrease the level of anti-inflammatory cytokine concentrations in patients with ACS as well. [18]

Other authors reported that TNF-α increase in acute MI not only more than control but also more than patients with stable angina, their results had statistically significant differences. [19, 20]
This might indicate that these cytokines had a role in acute events in addition to their role in the development of the chronic atherosclerotic process; the stable form of the disease (stable angina).

This study shows that despite hypertension is the commonest traditional risk factor, 72 (56.7%) patients. This study did not show any influence of hypertension on the level of TNF-α P. Value (0.73). (Table2). These were in agreement with other studies [21, 22]

Diabetes is the second most common risk factor in this study patient group with ACS

65 (52%) patients but there was no statistically significant influence of diabetes on the level of TNF-α in ACS patient group in comparison with non-diabetic. The P. values (0.945). This was inconsistent with others. [21, 22]

Thirty-six (28.8%) patients enrolled in this study had complications.

There were statistically significant differences in the mean level of TNF-α between patients with complications (24.91 pg/dl) and those without complications (21.93 pg/dl). (P. value 0.041), this was in accordance with other studies. [22-24]

Other authors reported an increase in the level of TNF-α not only associated with increase complication but with the severity of disease and the number of vessels that severely involved (>50%-70% luminal narrowing on angiogram)[23,24]

Ridker PM. and Manuel G. reported that raise TNF-α not only associated with in-hospital complication but an independent predictor of cardiovascular events at 6-month follow-up. [17, 25]

Deswal et al indicated that TNF-α was an independent predictor of mortality in patients with heart failure. [8]

**Conclusion:**
This study indicated that TNF-α level was a good indicator of acute coronary events and predictor of severity and complications of the disease.

**References:**
2- Bossowska A., Kiersnowska-Rogowska B., Bossowski A., Galar B., Sowiński P., Cytokines in patients with ischaemic heart disease or myocardial infarction,2003; 59(8):105-14

www.ijmshr.com


### Table 1: The mean of TNF-α among different type of ACS

<table>
<thead>
<tr>
<th></th>
<th>NO. of pts</th>
<th>Mean of TNF-α</th>
<th>SD</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>75</td>
<td>29.18</td>
<td>24.28</td>
<td></td>
</tr>
<tr>
<td>NSTEMI</td>
<td>21</td>
<td>26.66</td>
<td>19.60</td>
<td>0.001*</td>
</tr>
<tr>
<td>UNSTABLE ANGINA</td>
<td>29</td>
<td>20.76</td>
<td>21.93</td>
<td></td>
</tr>
<tr>
<td>CONTROL</td>
<td>120</td>
<td>9.21</td>
<td>6.47</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: The relationship of TNF-α with some risk factors

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>No. of pts</th>
<th>TNF-α</th>
<th>p. value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>68 (54.4)</td>
<td>24.39</td>
<td>0.16</td>
</tr>
<tr>
<td>Female</td>
<td>57 (45.6)</td>
<td>30.70</td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>39 (31.2)</td>
<td>27.59</td>
<td>0.80</td>
</tr>
<tr>
<td>No</td>
<td>67 (53.6)</td>
<td>26.51</td>
<td></td>
</tr>
<tr>
<td>x-smoker</td>
<td>19 (15.2)</td>
<td>30.69</td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>20 (16%)</td>
<td>32.8</td>
<td>0.25</td>
</tr>
<tr>
<td>No</td>
<td>105 (84)</td>
<td>26.44</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>72 (57.6)</td>
<td>32.99</td>
<td>0.73</td>
</tr>
<tr>
<td>No</td>
<td>53 (42.2)</td>
<td>28.30</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>65 (52)</td>
<td>27.83</td>
<td>0.945</td>
</tr>
<tr>
<td>No</td>
<td>60 (48)</td>
<td>27.54</td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>28 (23.2)</td>
<td>25.83</td>
<td>0.475</td>
</tr>
<tr>
<td>No</td>
<td>97 (76.8)</td>
<td>29.58</td>
<td></td>
</tr>
</tbody>
</table>
Table 3 The level of TNF-α between patients with complications and patients without complications

<table>
<thead>
<tr>
<th></th>
<th>NO. patients</th>
<th>Mean of TNF-α Pg/dl</th>
<th>SD</th>
<th>P. value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complication</td>
<td>36</td>
<td>33.46</td>
<td>24.91</td>
<td>0.041</td>
</tr>
<tr>
<td>Without</td>
<td>89</td>
<td>24.15</td>
<td>21.93</td>
<td></td>
</tr>
</tbody>
</table>

Table 4 The mean of TNF-α in patient with complications (HF & others)

<table>
<thead>
<tr>
<th></th>
<th>NO. of pts.</th>
<th>TNF-α (mean pg/dl)</th>
<th>SD</th>
<th>P. value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure</td>
<td>24</td>
<td>35.19</td>
<td>26.37</td>
<td></td>
</tr>
<tr>
<td>Other complications</td>
<td>7</td>
<td>36.69</td>
<td>26.9</td>
<td>0.897</td>
</tr>
<tr>
<td>Heart failure plus Other</td>
<td>5</td>
<td>35.58</td>
<td>13.73</td>
<td></td>
</tr>
<tr>
<td>complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>36</td>
<td>33.46</td>
<td>24.911</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: The mean level of TNF-α among various form of ACS in different gender

<table>
<thead>
<tr>
<th>Gender</th>
<th>STEMI</th>
<th>NSTEMI</th>
<th>UN</th>
<th>Control</th>
<th>P.value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>31.20</td>
<td>22.01</td>
<td>11.17</td>
<td>10.47</td>
<td>0.210</td>
</tr>
<tr>
<td>Female</td>
<td>37.72</td>
<td>24.02</td>
<td>17.15</td>
<td>10.75</td>
<td></td>
</tr>
</tbody>
</table>